Latest News

2018 FNIH Lurie Prize awarded for DNA immune response discovery


 

The Foundation of the National Institutes of Health has awarded Zhijian “James” Chen, PhD, the 2018 Lurie Prize in Biomedical Sciences for his discovery of the cyclic GMP-AMP synthase (cGAS) enzyme, according to a statement released Tuesday, April 3.

“We are proud to honor Dr. Chen with the 2018 Lurie Prize in Biomedical Sciences for the discovery of the cGAS enzyme and pathway and their unique role in immune and inflammatory response,” Maria C. Freire, PhD, president and executive director of the FNIH, said in a press release. “Dr. Chen joins five other Lurie Prize winners, who are shaping the future of human health through their profound biomedical research.”

While scientists have known for some time that DNA had a role in activating the immune response, the specifics of the process eluded explanation.

Dr. Zhijian Chen the George L. MacGregor Distinguished Chair in Biomedical Science and professor of molecular biology at the University of Texas Southwestern Medical Center, Dallas

Dr. Zhijian Chen

“A key gap in our understanding was the sensor that detects DNA, and so we set out to try to fill in this gap,” Dr. Chen explained in a phone interview. “We utilized a biochemical approach to identify the DNA sensor and eventually identify cGAS.”

Through their work, Dr. Chen and his team uncovered that cGAS was the enzyme used to spark the reaction.

“[cGAS] is a protein sensor that detects DNA as a danger signal that then triggers the immune response,” said Dr. Chen. “When DNA gets into the cytoplasm, cGAS becomes activated and catalyzes the synthesis of a small molecule, called cGAMP, which then functions as a messenger that activates the immune response pathway.”

While the cGAS enzyme can help defend against infectious disease or cancer, the enzyme can also trigger autoimmune diseases such as rheumatoid arthritis.

Pages

Recommended Reading

Treat to target in RA: Finding the right path forward
MDedge Rheumatology
Immunotherapy regimen influences inflammatory arthritis presentation
MDedge Rheumatology
Xeljanz: FDA panel recommends ulcerative colitis indication
MDedge Rheumatology
Arthritis limits physical activity the most in the South
MDedge Rheumatology
Study links RA flares after joint replacement to disease activity, not medications
MDedge Rheumatology
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Rheumatology
TB in 2017: Good news and bad news
MDedge Rheumatology
Cancer groups offer guidance on musculoskeletal adverse events related to checkpoint inhibitors
MDedge Rheumatology
Certolizumab pegol: Has serious infection risk been overstated?
MDedge Rheumatology
Few acutely ill hospitalized patients receive VTE prophylaxis
MDedge Rheumatology